A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line

BACKGROUND: Although chronic myeloid leukemia (CML) treatment has improved since the introduction of imatinib mesylate (IM), cases of resistance have been reported. This resistance has been associated with the emergence of multidrug resistance (MDR) phenotype, as a BCR-ABL independent mechanism. The...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Corrêa, Stephany, Pizzatti, Luciana, Du Rocher, Bárbara, Mencalha, André, Pinto, Daniela, Abdelhay, Eliana
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2012
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3361502/
https://ncbi.nlm.nih.gov/pubmed/22458888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1477-5956-10-23
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi